Kelly Aaron S, Fox Claudia K
Department of Pediatrics, University of Minnesota Masonic Children's Hospital, University of Minnesota Medical School, 420 Delaware St. S.E., MMC 715, Minneapolis, MN, 55455, USA.
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Curr Diab Rep. 2017 Aug;17(8):55. doi: 10.1007/s11892-017-0886-z.
This review provides a rationale for the use of pharmacotherapy in pediatric weight management, summarizes results of some of the key pediatric clinical trials of approved and "off-label" obesity medications, introduces new options in the pediatric pipeline, and offers a glimpse into the future of pediatric obesity medicine.
Despite the need for adjunctive treatments to enhance the outcomes of lifestyle modification therapy among youth with obesity, none of the obesity medications evaluated to date have been shown to meaningfully reduce BMI or cardiometabolic risk factors. Promising medications recently approved for the treatment of obesity in adults will soon be tested in pediatric trials, offering hope that new therapeutic options will soon be available. As new medications are approved to treat pediatric obesity, it will be important to evaluate the safety and efficacy of combination pharmacotherapy and investigate predictors of response. Application of precision medicine approaches to the field of pediatric obesity management will improve the long-term outlook for the tens of millions of youth afflicted with this serious and recalcitrant disease.
本综述为药物治疗在儿童体重管理中的应用提供理论依据，总结一些已批准和“非标签”使用的肥胖症药物的关键儿科临床试验结果，介绍儿科领域的新选择，并展望儿童肥胖医学的未来。
尽管需要辅助治疗来提高肥胖青少年生活方式改变疗法的效果，但迄今为止评估的所有肥胖症药物均未显示能显著降低体重指数或心血管代谢危险因素。最近批准用于治疗成人肥胖症的有前景的药物很快将在儿科试验中进行测试，有望很快提供新的治疗选择。随着新药物被批准用于治疗儿童肥胖症，评估联合药物治疗的安全性和有效性并研究反应预测因素将很重要。将精准医学方法应用于儿童肥胖管理领域将改善数千万患有这种严重且难治性疾病的青少年的长期前景。
